… intravenous immunoglobulin (hdIVIg) in resistant autoimmune blistering disease is
increasing… It offers a potentially attractive therapeutic approach in this range of antibody‐mediated …

… -threatening diseases, clinically characterized by blisters and … clinical criteria, autoimmune
bullous diseases are classified … (subepidermal blistering diseases, eg, pemphigoid diseases …

… intravenous immune globulin (IVIG) is used to treat a wide variety of autoimmune diseases.
We … with autoimmune blistering diseases, namely epidermolysis bullosa acquisita (EBA), two; …

… Conventional therapy The treatment of autoimmune blistering diseases is often investigator-driven
and based on local practices. There is no universal agreement on what is considered …

… This report highlights major studies and the best evidence to date regarding the treatment
of autoimmune skin blistering diseases with IVIg, providing an update on its efficacy, proposed …

… are when multiple conventional treatments have been … treatment-resistant autoimmune
blistering disorders (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, pemphigoid …

… the current published data on the use of intravenous immunoglobulin (IVIg) therapy in the
treatment of autoimmune mucocutaneous blistering diseases (AMBDs) and to discuss the …

… We sought to evaluate the outcome of the use of IVIg in patients with autoimmune
mucocutaneous blistering diseases refractory to conventional therapy or with contraindications for it. …

… or refractory autoimmune blistering diseases under IVIG therapy. … IVIG therapy is efficient
and safe for refractory autoimmune … patients with refractory autoimmune blistering disease, that …

… the efficacy of IVIg therapy in autoimmune mucocutaneous blistering diseases (AMBDs).
We searched the PubMed database for studies on pemphigus and pemphigoid using the …